NEWS & ARCHIVE
ABOUT US
R & D
R & D
Contact Us
Links
 

Fostrap is designed to benefit patients who have abnormally high blood levels of phosphorus (hyperphosphataemia) as a result of kidney malfunction or renal failure. Hyperphosphataemia is a prime cause of vascular calcification and may lead to patients suffering additional clinical complications in the form of heart disease, bone disease and joint problems.

The novelty of CM&D’s products lies in their potential to start binding phosphorus in the saliva. In the first stage products will be developed as complementary to current therapies so as to offer another pharmacological tool to doctors in their daily fight against hyperphosphataemia.
The clinical development of Fostrap is already under way, with preliminary results published in the Journal of the American Society of Nephrology. Launch is expected in 2010.
 
Back to R & D menu
 
CURRENT NEWS :
© 2009 CM&D Pharma Limited. All rights reserved. Terms & Conditions.